Therefore, the interpretation of a TP53 variant detected in a small fraction of reads in a breast cancer patient requires careful analysis integrating the type and stage of the tumour, the age of the patient, and the treatments and will often require complementary genetic investigations performed on other tissues. This evidence concerns the gene TP53 and breast carcinoma.